lestaurtinib has been researched along with Acute Myelogenous Leukemia in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 13 (43.33) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Choi, SJ; Choi, SU; Han, SY; Kim, YC; Lee, SD; Moon, MJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Hu, B; Mohty, M; Savani, BN; Vikas, P | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Kantarjian, HM; Konopleva, M; Luthra, R; Ravandi, F | 1 |
| Al-Jamal, HA; Hassan, R; Johan, MF; Mat Jusoh, SA | 1 |
| Burnett, AK; Cavenagh, JD; Gale, RE; Gilkes, A; Grunwald, MR; Hills, RK; Jones, G; Kjeldsen, L; Knapper, S; Konig, H; Levis, MJ; Russell, N; Thomas, I | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Gore, SD | 1 |
| Tallman, M | 1 |
| Karp, J | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Shabbir, M; Stuart, R | 1 |
| Fathi, AT; Levis, M | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Advani, A; Amadori, S; Baccarani, M; Baer, MR; Bensen-Kennedy, DM; Coutre, S; Cripe, LD; Douer, D; Erba, H; Godley, LA; Juliusson, G; Kantarjian, HM; Langston, AA; Levis, M; Lewis, ID; Litzow, MR; Meloni, G; Nagler, A; Perl, A; Petersdorf, S; Ravandi, F; Sanz, M; Sato, T; Small, D; Smith, BD; Stone, R; Stuart, RK; Tallman, MS; Tremmel, L; Wang, ES; Wiktor-Jedrzejczak, W; Yee, K | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Eyre, T; Grech, H; King, AJ; Rangarajan, D; Sampson, R | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Alonzo, TA; Arceci, R; Brown, P; Gerbing, R; Lange, B; Levis, M; Meshinchi, S; Small, D | 1 |
| Kim, KT; Levis, M; Li, L; McNiece, I; Murphy, KM; Pham, R; Small, D; Smith, BD; Stine, A | 1 |
| Zhang, GS | 1 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| Cheng, L; Kim, KT; Levis, M; Li, L; Nguyen, HB; Piloto, O; Small, D; Ye, Z; Yu, X | 1 |
| Ehninger, G; Illmer, T | 1 |
| Gale, RE; Khwaja, A; Kottaridis, PD; Linch, DC; Matsuda, S; Mead, AJ | 1 |
| Gary Gilliland, D; Tam, WF | 1 |
| Allebach, J; Baldwin, BR; Dionne, C; Jones-Bolin, S; Levis, M; Ruggeri, B; Small, D; Smith, BD; Tse, KF; Zheng, R | 1 |
10 review(s) available for lestaurtinib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous | 2014 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2010 |
Lestaurtinib: a multi-targeted FLT3 inhibitor.
Topics: Carbazoles; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors | 2009 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Can FLT3 inhibitors overcome resistance in AML?
Topics: Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Piperazines; Quinazolines; Staurosporine | 2008 |
2 trial(s) available for lestaurtinib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Child; Child, Preschool; Consolidation Chemotherapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Young Adult | 2017 |
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Chemotherapy, Adjuvant; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutant Proteins; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Young Adult | 2011 |
18 other study(ies) available for lestaurtinib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Leukemia, Myeloid, Acute | 2010 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Topics: Apoptosis; Azacitidine; Carbazoles; Cell Line, Tumor; Cells, Cultured; DNA Methylation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor | 2015 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
Acute isolated transmural neutropenic gastritis.
Topics: Acute Disease; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Daunorubicin; Factor VII Deficiency; Female; Furans; Gastritis; Granulocyte Colony-Stimulating Factor; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Topics: Adolescent; Apoptosis; Carbazoles; Cell Survival; Child; Child, Preschool; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Infant; Leukemia, Myeloid, Acute; Ligands; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Prognosis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Risk Factors; Tumor Cells, Cultured | 2004 |
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Aged; Animals; Antigens, CD; Antigens, CD34; Base Sequence; Carbazoles; Cell Separation; DNA, Neoplasm; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Humans; Indoles; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplastic Stem Cells; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tandem Repeat Sequences; Transplantation, Heterologous | 2005 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; Carbazoles; Cell Cycle; Cell Differentiation; Cell Line, Transformed; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cyclin D3; Cyclins; fms-Like Tyrosine Kinase 3; Furans; Gene Expression; Genes, myc; HIV-1; Humans; Indoles; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-pim-1; Stem Cells; Transduction, Genetic; Transfection | 2007 |
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Tandem Repeat Sequences | 2008 |
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Carbazoles; Cell Survival; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Kinetics; Leukemia, Myeloid, Acute; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Point Mutation; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |